Masimo's announcement of preliminary revenue figures that meet consensus estimates is likely to be viewed positively by investors, but since the figures are in line with expectations, the short-term impact on the stock price is expected to be neutral. The detailed breakdown between healthcare and non-healthcare revenue provides transparency and may reassure investors about the company's diversified revenue streams.